



HANDBOOK OF MODERN PHARMACEUTICAL ANALYSIS

Edited by Satinder Ahuja
and Stephen Scypinski



VOLUME 3

Series Editor **Satinder Ahuja**



SEPARATION SCIENCE AND TECHNOLOGY

**HANDBOOK OF MODERN
PHARMACEUTICAL ANALYSIS**

This Is Volume III of
SEPARATION SCIENCE AND TECHNOLOGY
A reference series edited by Satinder Ahuja

HANDBOOK OF MODERN PHARMACEUTICAL ANALYSIS

Edited by

Satinder Ahuja

*Ahuja Consulting
Calabash, North Carolina*

Stephen Scypinski

*RW Johnson Pharmaceutical Research Institute
Raritan, New Jersey*



ACADEMIC PRESS

A Harcourt Science and Technology Company

San Diego San Francisco New York Boston London Sydney Tokyo

This book is printed on acid-free paper. ☺

Copyright © 2001 by Academic Press

All rights reserved.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the publisher.

The appearance of the code at the bottom of the first page of a chapter in this book indicates the Publisher's consent that copies of the chapter may be made for personal or internal use of specific clients. This consent is given on the condition, however, that the copier pay the stated per-copy fee through the Copyright Clearance Center, Inc. (222 Rosewood Drive, Danvers, Massachusetts 01923), for copying beyond that permitted by Sections 107 or 108 of the U.S. Copyright Law. This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale. Copy fees for pre-2001 chapters are as shown on the title pages; if no fee code appears on the title page, the copy fee is the same as for current chapters. 01 \$35.00.

The information provided in this handbook is compiled from reliable sources but the authors, editor, and the publisher cannot assume any responsibility whatsoever for the validity of all statements, illustrations, data, procedures, and other related materials contained herein or for the consequence of their use.

ACADEMIC PRESS

A Harcourt Science and Technology Company

525 B Street, Suite 1900, San Diego, CA 92101-4495, USA

<http://www.academicpress.com>

Academic Press

Harcourt Place, 32 Jamestown Road, London, NW1 7BY, UK

Library of Congress Catalog Number: 2001088201

International Standard Book Number: 0-12-045555-2

Printed in the United States of America

00 01 02 03 HP 9 8 7 6 5 4 3 2 1

CONTENTS

CONTRIBUTORS xiii

PREFACE xvii

1 Modern Pharmaceutical Analysis: An Overview

SATINDER AHUJA

- I. Identity and Purity Requirements 2
- II. Bioavailability/Dissolution Requirements 4
- III. Regulatory Considerations 5
- IV. Regulatory Compliance 8
- V. International Conference on Harmonization 9
- VI. Global CMC NDA 9
- VII. Highlights of Modern Pharmaceutical Analysis 10
- References 22

2 Combinatorial Chemistry and High-Throughput Screening in Drug Discovery and Development

KEN APPELL, JOHN J. BALDWIN, AND WILLIAM J. EGAN

- I. Introduction 24
- II. Combinatorial Methods 25

- III. Methods for Structural Assignment 26
- IV. Diversity 28
- V. Druglikeness 28
- VI. Designing Combinatorial Libraries with Optimal ADME Properties 28
- VII. Existing Computational Methods for ADME Properties 30
- VIII. Optimization Philosophy 35
- IX. Applying Existing ADME Models to Combinatorial Library Design 37
- X. The Future of ADME Modeling 38
- XI. High-Throughput Screening and Combinatorial Chemistry 39
- XII. Assay Plate Formats: Move to Miniaturization 40
- XIII. Nonseparation or Homogeneous Assays 43
- XIV. Identification of Receptor Antagonists for Chemokine Receptor and Bradykinin-1 by Screening a 150,000-Member Combinatorial Library 44
- XV. Structure-based Design of Somatostatin Agonists 47
- XVI. Conclusions 48
- References 49

3 Solid-State Analysis

HARRY G. BRITTAIN

- I. Introduction 57
- II. Properties Associated with the Molecular Level 58
- III. Properties Associated with the Particulate Level 65
- IV. Properties Associated with the Bulk Level 73
- V. Summary 81
- References 81

4 Degradation and Impurity Analysis for Pharmaceutical Drug Candidates

KAREN M. ALSANTE, ROBERT C. FRIEDMANN, TODD D. HATAJIK, LINDA L. LOHR,
THOMAS R. SHARP, KIMBERLY D. SNYDER, AND EDWARD J. SZCZESNY

- I. Residual Solvents and Water 86
- II. Purposeful Degradation Studies 95
- III. Isolation and Identification of Impurities/Degradants 119
- IV. Mass Spectrometry in Identification of Impurities 127
- V. Role of NMR 147
- VI. Reference Standards 166
- VII. Summary 168
- References 168

5 Preformulation Studies

EDWARD LAU (deceased)

- I. Introduction 173
- II. Preformulation Studies 180
- III. Analytical Techniques and Instruments for Preformulation Studies 214
- IV. Regulatory Requirements for Preformulation 224
- V. Summary and Conclusions 226
 - Appendix 1 227
 - Appendix 2 229
 - Appendix 3 232
 - References 232

6 Solid Dosage-Form Analysis

PHILIP J. PALERMO

- I. Introduction 235
- II. Physicochemical Characterization Techniques 241
- III. Near-Infrared Analysis 252
- IV. Automation 257
- V. Future Directions 262
- VI. Summary 263
- VII. Acknowledgments 263
 - References 263

7 Parenteral Dosage Forms

GREGORY A. BIRRER, SATYA S. MURTHY, AND JIE LIU

- I. Characteristics of Parenteral Dosage Forms 270
- II. Pharmaceutical Analysis During Formulation and Process Development 271
- III. Analytical Testing for Finished Parenteral Products 272
- IV. Packaging Components Testing 273
- V. Process Development Support 274
- VI. In-Process Testing 275
- VII. Release Testing 276
- VIII. Raw Material Testing 278
- IX. Validation of Analytical Procedure 279
 - X. Stability-Indicating Methods 281
 - XI. Method Transfer 281
 - XII. Cleaning Method Validation 282
- XIII. Admixture Studies 282
- XIV. Microbiological Testing of Parenteral Formulations 283
- XV. Sterility Testing 284

XVI. Bacterial Endotoxin Testing	290
XVII. Particulate Matter Testing	292
XVIII. Bioburden Testing of Parenteral Product Solution	294
XIX. Introduction to Cleaning Validation	298
XX. Swab Selection (Recovery and Compatability Studies)	298
XXI. Technician Qualification	298
XXII. Sampling	299
XXIII. Acceptance Criteria	300
XXIV. Methods of Analysis	301
XXV. Grouping/Matrix Approach	301
XXVI. Validation Protocol	302
XXVII. Validation Report	302
XXVIII. Summary	302
References	303

8 New Drug Delivery Systems

DAVID C. PANG

I. Introduction	307
II. Oral Drug Delivery	308
III. Direct Drug Delivery	310
IV. Dermatological Delivery System	311
V. Tumor-Targeted Drug Delivery Systems	311
VI. Biodegradable Drug Delivery System	313
VII. Protein Drug Delivery System	315
VIII. Devices	319
IX. Summary	323
References	323

9 Compendial Testing

CHRISTINE F. RICHARDSON

I. Introduction	325
II. A Brief History of the United States Pharmacopeia	326
III. Compendial Testing for Formulated Products and Active Ingredients	327
IV. Which Compendium to Use and When to Use It	340
V. Validation	340
VI. Harmonization of Testing Methods for Multicountry Submission	342
VII. Conclusions	343
VIII. Acknowledgments	344
References	344

10 Method Development

HENRIK T. RASMUSSEN

- I. Introduction 345
- II. Overview of Separation Methods 346
- III. High-Performance Liquid Chromatography 349
- IV. Thin-Layer Chromatography 374
- V. Gas Chromatography 375
- VI. Supercritical-Fluid Chromatography 376
- VII. Capillary Electrophoresis 379
- VIII. Conclusions 383
- IX. Summary 383
- References 384

11 Setting Up Specifications

IAN E. DAVIDSON

- I. Introduction 387
- II. Setting Specifications at Different Stages of Drug Development 389
- III. International Conference on Harmonization Guidelines 393
- IV. Pharmacopeias and Specifications 410
- V. Statistical Considerations in Setting Specifications 411
- VI. Summary 412
- References 412

12 Validation of Pharmaceutical Test Methods

JONATHAN B. CROWTHER

- I. Background and Chapter Overview 415
- II. Validation Terminology and Definitions 418
- III. Method Development and Its Influence on Method Validation 419
- IV. Validation Requirements of The Method 428
- V. Validation Documentation 428
- VI. Validation Experimentation 429
- VII. Method Transfer 436
- VIII. Revalidation 438
- IX. Reference Standards 438
- X. Summary 441
- Acknowledgments 442
- References 442

13 Stability Studies

JESSICA CHA, JOSEPH S. RANWEILER, PHILIP A. LANE

- I. Introduction 445
- II. Operational Issues 446
- III. Excipients 461
- IV. Drug Substance 463
- V. Drug Product 471
- VI. Summary 480
- Glossary 480
- Appendix 482
- References 483

14 Analytical Methodology Transfer

STEPHEN SCYPINSKI

- I. Introduction 485
- II. The Drug Development Process 486
- III. Types of Method Transfer 487
- IV. Requirements and Elements of Analytical Technology Transfer 489
- V. Technical Transfer Time Line/Project Plan 492
- VI. Analysis of Results/Statistical Packages 493
- VII. Analyst Certification and Training 494
- VIII. Transfer of Technical Ownership 494
- IX. Chapter Summary 497
- References 497

15 Pharmaceutical Analysis Documentation

HITESH CHOKSHI AND KATHLEEN SCHOSTACK

- I. Scope 499
- II. Introduction 500
- III. Pharmaceutical Analysis During Product Life Cycle 500
- IV. Regulatory Documents 510
- V. Compliance Documents 516
- VI. Research Documents 520
- VII. Summary 521
- VIII. Conclusions 522
- Appendix I: References for CMC Guidances 522
- Appendix II: U.S. NDA Table of Contents—Analytical Documentation 525

16 An Innovative Separation Platform: Electrophoretic Microchip Technology

LIAN JI JIN, JEROME FERRANCE, ZHILI HUANG, AND JAMES P. LANDERS

- I. Introduction 529
- II. Microchip Fabrication 531
- III. Detection Techniques 535
- IV. Pharmaceutical Potential 545
- V. Concluding Remarks 549
- VI. Summary 549
 - References 549

INDEX 555

This Page Intentionally Left Blank

CONTRIBUTORS

Numbers in parentheses indicate the pages on which the authors' contributions begin.

Satinder Ahuja (1) Ahuja Consulting, 330 Middleton Drive, Suite 803, Calabash, North Carolina 28467

Karen M. Alsante (85) Pfizer Global Research and Development Division, Analytical Research and Development, P.O. Box 4077, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340

Ken Appell (23) Pharmacopeia, Inc., P.O. Box 5350, Princeton, New Jersey 08543-5350

John J. Baldwin (23) Pharmacopeia, Inc., P.O. Box 5350, Princeton, New Jersey 08543-5350

Gregory A. Birrer (269) Baxter Anesthesia Critical Care, Baxter Healthcare Medication Delivery, 95 Spring Street, New Providence, New Jersey 07974

Harry G. Brittain (57) Center for Pharmaceutical Physics, 10 Charles Road, Milford, New Jersey 08848

Jessica Cha (445) The R. W. Johnson Pharmaceutical Research Institute, P.O. Box 300, Route 202, Raritan, New Jersey, 08869

Hitesh Chokshi (499) Hoffmann-La Roche, Inc. 340, Kingsland Street, Nutley, New Jersey 07110

- Jonathan B. Crowther** (415) Ortho-Clinical Diagnostics, 1001 U.S. Highway 202, Raritan, New Jersey, 08869-0606
- Jan E. Davidson** (387) Aventis Pharmaceuticals, P.O. Box 6800, Route 202-206, Bridgewater, New Jersey 08560
- William J. Eagan** (23) Pharmacopeia, Inc., P.O. Box 5350, Princeton, New Jersey 08543-5350
- Judy Estrada** (269) Gensia-Sicor Pharmaceuticals, 19 Hughes Street, Irvine, California 92618-1902
- Jerome Ferrance** (ch. 16) Department of Chemistry, University of Virginia, McCormick Road, Charlottesville, Virginia 22901
- Robert C. Friedmann** (85) Pfizer Global Research and Development Division, Process Research and Development, P.O. Box 4077, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340
- Todd D. Hatajik** (85) Pfizer Global Research and Development Division, Analytical Research and Development, P.O. Box 4077, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340
- Zhili Huang** (529) Department of Chemistry, University of Virginia, McCormick Road, Charlottesville, Virginia 22901
- Lian Ji Jin** (ch. 16) Department of Chemistry, University of Virginia, McCormick Road, Charlottesville, Virginia 22901
- James P. Landers** (529) Department of Chemistry, University of Virginia, and Department of Pathology, University of Virginia Health Science Center, Charlottesville, Virginia 22901
- Philip A. Lane** (445) The R. W. Johnson Pharmaceutical Research Institute, P.O. Box 300, Route 202, Raritan, New Jersey 08869
- Edward P. Lau** (173) (deceased) E. L. Associates, 102 Lanark Road, Wilmington, Delaware 19807
- Jie Liu** (269) Baxter Anesthesia Critical Care, Baxter Healthcare Medication Delivery, 95 Spring Street, New Providence, New Jersey 07974
- Linda L. Lohr** (85) Pfizer Global Research and Development Division, Analytical Research and Development, P.O. Box 4077, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340
- Satya S. Murthy** (269) Baxter Anesthesia Critical Care, Baxter Healthcare Medication Delivery, 95 Spring Street, New Providence, New Jersey 07974
- Philip J. Palermo** (235) Purdue Pharma L. P., 444 Saw Mill River Road, Ardsley, New York 10502
- David C. Pang** (307) American Association of Pharmaceutical Scientists, 2107 Wilson Boulevard, #700, Arlington, Virginia 22201-3046
- Joseph S. Ranweiler** (445) The R. W. Johnson Pharmaceutical Research Institute, P.O. Box 300, Route 202, Raritan, New Jersey 08869
- Henrik T. Rasmussen** (345) Analytical Chemistry Research and Development, The R. W. Johnson Pharmaceutical Research Institute, 1000 Route 202, Raritan, New Jersey 08869